UroGen Pharma Ltd. (URGN) Bundle
Understanding UroGen Pharma Ltd. (URGN) Revenue Streams
Understanding UroGen Pharma Ltd.’s Revenue Streams
The primary revenue source for the company is the product Jelmyto. In the three months ended September 30, 2024, revenue from Jelmyto was $25.2 million, compared to $20.9 million for the same period in 2023, marking a year-over-year increase of 15.8%. For the nine months ended September 30, 2024, total revenue was $65.8 million, an increase from $59.2 million in 2023, representing a growth rate of 11.8%.
The following table provides a detailed breakdown of revenue from Jelmyto for the three and nine months ended September 30, 2024, and 2023:
| Period | Revenue (in millions) | Percentage Change |
|---|---|---|
| Three Months Ended September 30, 2024 | $25.2 | 15.8% |
| Three Months Ended September 30, 2023 | $20.9 | - |
| Nine Months Ended September 30, 2024 | $65.8 | 11.8% |
| Nine Months Ended September 30, 2023 | $59.2 | - |
In the third quarter of 2024, the company recognized $2.6 million from CREATES Act sales, an increase from $1.1 million in the third quarter of 2023. This growth is attributed to higher sales volumes, which were partially offset by increased revenue reserves due to estimated Medicare refunds for discarded drugs.
For the nine months ended September 30, 2024, CREATES Act sales reached $2.8 million, compared to $2.0 million in the same period in 2023. The following table summarizes the revenue contributions from the CREATES Act for both periods:
| Period | CREATES Act Revenue (in millions) |
|---|---|
| Three Months Ended September 30, 2024 | $2.6 |
| Three Months Ended September 30, 2023 | $1.1 |
| Nine Months Ended September 30, 2024 | $2.8 |
| Nine Months Ended September 30, 2023 | $2.0 |
Overall, the growth in revenue is primarily driven by the increased demand for Jelmyto, reflecting the company’s focus on expanding its market presence and addressing unmet medical needs in urothelial cancer treatment.
As of September 30, 2024, the company reported an accumulated deficit of $768.7 million, highlighting the ongoing challenges in achieving profitability despite the growth in revenue. The total operating expenses for the nine months ended September 30, 2024, were $128.5 million, up from $103.0 million in the previous year, indicating a significant investment in research, development, and commercialization efforts to support future revenue growth.
A Deep Dive into UroGen Pharma Ltd. (URGN) Profitability
A Deep Dive into UroGen Pharma Ltd.'s Profitability
Gross Profit Margin: For the three months ended September 30, 2024, gross profit was $22.8 million with a gross profit margin of approximately 90.3%. In comparison, for the same period in 2023, gross profit was $18.5 million with a margin of 88.6%. For the nine months ended September 30, 2024, gross profit reached $59.4 million, resulting in a gross profit margin of 90.2% compared to $52.1 million and a margin of 88.1% in 2023.
Operating Profit: The operating loss for the three months ended September 30, 2024, was $17.5 million, while for the same period in 2023, it was $13.5 million. For the nine months ended September 30, 2024, the operating loss increased to $69.1 million from $50.9 million in 2023.
Net Profit Margin: The net loss for the three months ended September 30, 2024, was $23.7 million, resulting in a net profit margin of -94%. For the same period in 2023, the net loss was $21.9 million, indicating a net profit margin of -105%. For the nine months ended September 30, 2024, the net loss was $89.4 million, corresponding to a net profit margin of -136%, compared to -128% with a net loss of $76.2 million in 2023.
Trends in Profitability Over Time
Over the past year, the gross profit has shown an upward trend due to increased sales volume of Jelmyto. However, operating and net losses have widened significantly, reflecting escalating operational costs, especially in research and development and marketing expenses.
Comparison of Profitability Ratios with Industry Averages
As of September 30, 2024, the gross profit margin of 90.3% exceeds the biotechnology industry average of approximately 70-80%. Conversely, the net profit margin of -136% is significantly below the industry average, indicating financial challenges in profitability relative to peers.
Analysis of Operational Efficiency
The company reported that total operating expenses for the three months ended September 30, 2024, were $40.3 million, a significant increase from $32.0 million in the same period in 2023. The breakdown of operating expenses is as follows:
| Expense Type | Q3 2024 (in millions) | Q3 2023 (in millions) |
|---|---|---|
| Research and Development | 11.4 | 10.2 |
| Selling and Marketing | 17.8 | 12.6 |
| General and Administrative | 11.2 | 9.2 |
| Total Operating Expenses | 40.3 | 32.0 |
The increase in operating expenses, particularly in selling and marketing, reflects the company's aggressive strategy to expand its market presence. The operational efficiency is under pressure due to these rising costs, which are not yet matched by corresponding revenue growth.
Debt vs. Equity: How UroGen Pharma Ltd. (URGN) Finances Its Growth
Debt vs. Equity: How UroGen Pharma Ltd. Finances Its Growth
Overview of the Company's Debt Levels:
As of September 30, 2024, UroGen Pharma Ltd. reported total liabilities of $276.4 million. The company has a mix of short-term and long-term debt, which includes:
- Short-term debt: approximately $3.3 million due under the prepaid forward obligation.
- Long-term debt: approximately $100 million from a loan agreement with Pharmakon, which was funded in two tranches of $75 million in March 2022 and $25 million in December 2022.
Debt-to-Equity Ratio:
The debt-to-equity ratio for UroGen Pharma Ltd. as of September 30, 2024, is calculated as follows:
| Total Debt | Total Equity | Debt-to-Equity Ratio |
|---|---|---|
| $276.4 million | $25.5 million | 10.84 |
This ratio indicates a substantial reliance on debt compared to equity, significantly higher than the industry average of approximately 1.5 to 2.0.
Recent Debt Issuances and Credit Ratings:
In March 2024, UroGen amended and restated its loan agreement with Pharmakon to include an additional third tranche of $25 million funded in September 2024. A fourth tranche of $75 million is available at the company's option, contingent upon FDA approval for UGN-102. The interest rate on the loans is based on the 3-month SOFR plus 7.25%. The credit rating specifics were not disclosed in the available documents.
Balancing Between Debt Financing and Equity Funding:
The company has utilized equity financing significantly, raising approximately $151.2 million from the issuance of ordinary shares and pre-funded warrants in the first nine months of 2024. UroGen Pharma has also entered into an ATM Sales Agreement allowing it to sell up to $100 million in ordinary shares, with approximately $27.3 million remaining available as of September 30, 2024.
As of September 30, 2024, the company reported cash and cash equivalents of $254.2 million, which indicates a solid liquidity position to support ongoing operations.
Assessing UroGen Pharma Ltd. (URGN) Liquidity
Assessing UroGen Pharma Ltd.'s Liquidity
Current Ratio: As of September 30, 2024, the current ratio was 5.92, calculated from current assets of $261.9 million and current liabilities of $44.3 million.
Quick Ratio: The quick ratio, excluding inventory, was 5.90, indicating solid short-term liquidity.
Analysis of Working Capital Trends
As of September 30, 2024, working capital stood at $217.6 million, reflecting an increase from $160.3 million as of December 31, 2023. This growth is primarily due to increased cash reserves and successful equity financing activities.
| Period | Current Assets (in millions) | Current Liabilities (in millions) | Working Capital (in millions) |
|---|---|---|---|
| December 31, 2023 | $261.9 | $51.6 | $210.3 |
| September 30, 2024 | $261.9 | $44.3 | $217.6 |
Cash Flow Statements Overview
For the nine months ended September 30, 2024, cash flows from operating activities were $(83.1 million), compared to $(63.4 million) in the same period of 2023. This increase in cash outflow is primarily due to higher operational expenses.
Cash flows from investing activities were $(81.2 million) in 2024, a significant drop from $10.4 million in 2023, reflecting increased investments in marketable securities.
Cash flows from financing activities amounted to $194.5 million in 2024, up from $116.9 million in 2023, driven by successful equity offerings and debt issuances.
| Cash Flow Type | 2024 (in millions) | 2023 (in millions) |
|---|---|---|
| Operating Activities | $(83.1) | $(63.4) |
| Investing Activities | $(81.2) | $10.4 |
| Financing Activities | $194.5 | $116.9 |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company held $254.2 million in cash and cash equivalents and marketable securities, providing a strong liquidity position. However, the company has also reported an accumulated deficit of $768.7 million, which raises concerns regarding its long-term sustainability without additional capital raises.
The financing obligations under the prepaid forward agreement and loans could impact future liquidity if sales targets are not met, necessitating careful cash flow management.
Is UroGen Pharma Ltd. (URGN) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, the company reported the following key financial metrics:
- Price-to-Earnings (P/E) Ratio: N/A (the company is not profitable)
- Price-to-Book (P/B) Ratio: 5.5 (calculated using total assets of $301,943,000 and total liabilities of $276,428,000, resulting in equity of $25,515,000)
- Enterprise Value-to-EBITDA (EV/EBITDA): N/A (given negative EBITDA)
The stock price trends over the last 12 months have shown fluctuations, with a current trading price of approximately $17.50 as of the latest public offering on June 20, 2024 .
No dividends are issued, reflecting a dividend yield of 0% and a payout ratio of 0% as the company has not declared any dividends in recent years due to ongoing operational losses.
Analyst consensus on stock valuation includes:
- Buy: 2 analysts
- Hold: 5 analysts
- Sell: 1 analyst
The following table summarizes the key financial data relevant to valuation:
| Metric | Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | N/A |
| Price-to-Book (P/B) Ratio | 5.5 |
| Enterprise Value-to-EBITDA (EV/EBITDA) | N/A |
| Current Stock Price | $17.50 |
| Dividend Yield | 0% |
| Payout Ratio | 0% |
| Analyst Consensus (Buy/Hold/Sell) | 2/5/1 |
Current financial performance indicates an accumulated deficit of $768.7 million as of September 30, 2024. The company continues to incur significant losses, with a net loss of $89.4 million for the nine months ended September 30, 2024.
Key Risks Facing UroGen Pharma Ltd. (URGN)
Key Risks Facing UroGen Pharma Ltd.
Overview of Internal and External Risks
The biotechnology sector presents significant risks, particularly for companies like UroGen Pharma Ltd. that are still developing their product lines. Key risk factors include:
- Industry Competition: The competitive landscape is intense, with numerous firms vying for market share in urothelial cancer treatments. The presence of established players with larger market capitalizations poses a threat to market penetration and pricing strategies.
- Regulatory Changes: The necessity for FDA approval for new treatments creates uncertainty. Delays or rejections in the approval process can significantly impact financial health and operational timelines.
- Market Conditions: Fluctuations in market conditions, including changes in healthcare policies and reimbursement rates, can adversely affect sales and profitability.
Operational Risks
Operational risks highlighted in recent earnings reports include:
- Research and Development Expenses: For the nine months ended September 30, 2024, research and development expenses were $42.3 million, up from $34.3 million in the same period in 2023, primarily due to increased manufacturing costs and clinical trials.
- Increased Selling and Marketing Expenses: Selling and marketing expenses rose to $53.8 million from $40.7 million year-over-year, driven by brand marketing costs for UGN-102 and overall operational expansion.
Financial Risks
Financial risks include:
- High Net Losses: The company reported a net loss of $89.4 million for the nine months ended September 30, 2024, compared to a loss of $76.2 million in 2023.
- Accumulated Deficit: As of September 30, 2024, the accumulated deficit stood at $768.7 million.
- Liquidity Risks: Although cash and cash equivalents were $254.2 million as of September 30, 2024, reliance on future financing remains critical.
Mitigation Strategies
To address these risks, UroGen Pharma has implemented several strategies:
- Financing Arrangements: The company has entered into an ATM Sales Agreement allowing for the sale of up to $100 million in ordinary shares. As of September 30, 2024, $27.3 million remains available under this agreement.
- Partnerships and Collaborations: Collaborations with RTW for funding and other strategic partnerships are in place to ensure continued financial support.
| Risk Factor | Description | Financial Impact |
|---|---|---|
| Regulatory Risks | Delays in FDA approvals for UGN-102 | Potential increase in R&D costs and delayed revenue generation |
| Market Competition | Intense competition from established companies | Pressure on pricing and market share |
| Financial Performance | Net loss of $89.4 million for 2024 YTD | Increased scrutiny from investors and potential funding challenges |
| Liquidity | Cash reserves of $254.2 million as of September 30, 2024 | Need for continuous capital raises to fund operations |
Future Growth Prospects for UroGen Pharma Ltd. (URGN)
Future Growth Prospects for UroGen Pharma Ltd.
Analysis of Key Growth Drivers
The primary growth driver for UroGen Pharma is the ongoing development and commercialization of its lead product, Jelmyto, which generated revenues of $25.2 million in the third quarter of 2024, up from $20.9 million in the same quarter of 2023. The company also benefits from the CREATES Act, which accounted for $2.6 million of sales in Q3 2024 compared to $1.1 million in Q3 2023.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, UroGen reported total revenues of $65.8 million, an increase from $59.2 million in 2023. Future projections suggest that continued market penetration and product expansion could lead to further revenue growth, driven by increased sales volumes and potential new product launches.
Strategic Initiatives or Partnerships That May Drive Future Growth
UroGen has secured a $75 million funding arrangement with RTW Investments to support the launch of Jelmyto and the development of its product candidates. Additionally, the company is advancing its pipeline, including UGN-102 and UGN-103, which are in various stages of clinical development.
Competitive Advantages That Position the Company for Growth
UroGen's competitive advantages include its proprietary RTGel technology, which enhances drug delivery, and its strong intellectual property portfolio. The company has also established partnerships for product development, such as its agreement with Agenus Inc. for the commercialization of zalifrelimab.
| Financial Metrics | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Revenue | $25.2 million | $20.9 million | +20.6% |
| Costs of Revenue | $2.5 million | $2.4 million | +4.2% |
| Research and Development Expenses | $11.4 million | $10.2 million | +11.8% |
| Selling and Marketing Expenses | $17.8 million | $12.6 million | +40.9% |
| General and Administrative Expenses | $11.2 million | $9.2 million | +21.7% |
As of September 30, 2024, UroGen's cash and cash equivalents totaled $254.2 million, providing a solid foundation for future growth initiatives. The company's strategic focus on expanding its product offerings and enhancing market presence positions it well to capitalize on emerging opportunities in the biotech sector.
UroGen Pharma Ltd. (URGN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- UroGen Pharma Ltd. (URGN) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of UroGen Pharma Ltd. (URGN)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View UroGen Pharma Ltd. (URGN)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.